



## Alameda County Health Advisory

### Monoclonal Antibody (MAB) Therapy Infusion Resources in Alameda County

March 8, 2021 (revised April 22, 2021)

The purpose of this Health Advisory is to inform clinicians in Alameda County about the availability of monoclonal antibody (MAB) therapy for high-risk patients with mild to moderate SARS-CoV-2 infections who are not yet hospitalized.

~~Bamlanivimab~~, [Bamlanivimab + etesevimab](#) and [casirivimab + imdevimab](#) are investigational MAB products available under Emergency Use Authorization (EUA) from the FDA. These products have been engineered to bind to and neutralize SARS-CoV-2 and prevent progression to severe illness. There are data suggesting that early treatment with MAB therapy may decrease the viral load and prevent some ED visits and hospitalizations in high-risk individuals.

#### Actions Requested of Clinicians

ACPHD recommends that clinicians with patients who meet the inclusion criteria for the use of MAB therapy, as described above, contact the following entities for information on treatment availability. Outpatients:

- ~~Washington Hospital COVID-19 Treatment Center: 510-818-6222~~ This site has been closed due to low patient volume.
- Stanford Health Care - ValleyCare, Pleasanton: [DL-SHC-VC-COVID@stanfordhealthcare.org](mailto:DL-SHC-VC-COVID@stanfordhealthcare.org)

LTCF Residents:

- Specialty Pharmacy associated with the LTCF

*If timely appointments in Alameda County are not available for your patients, you can contact the hospitals below:*

- UCSF: [UCSF Monoclonal Antibody Use Document](#) (complete/fax referral document, including for 12 to 17 year-olds). Questions? Contact [COVIDOutpatientTreatment@ucsf.edu](mailto:COVIDOutpatientTreatment@ucsf.edu)
- Stanford Medical Center, Palo Alto: [DL-SHC-PHARMACY-COVID@stanfordhealthcare.org](mailto:DL-SHC-PHARMACY-COVID@stanfordhealthcare.org)

**Inclusion criteria** for the use of outpatient monoclonal antibody therapy are as follows:

- Positive SARS-CoV-2 PCR or antigen test
- Mild to moderate COVID-19 symptoms for 10 days or less. Ideally, antibody therapy would begin within 3 days of a positive test.



- Hospital admission currently not needed
- Oxygen saturation is  $\geq 94\%$  on room air. The patient does not require supplemental  $O_2$  or an increase in baseline  $O_2$  flow rate.
- Weight is  $\geq 40$  kg
- Patient is at high risk for progressing to severe COVID-19 and/or hospitalization due to any of the following:
  - Body mass index (BMI)  $\geq 35$
  - Age  $\geq 65$  years of age
  - Diabetes, chronic kidney disease, immunosuppressive disease or current receipt of immunosuppressive treatment
  - Age  $\geq 55$  years of age with at least ONE of the following:
    - Cardiovascular disease
    - Hypertension
    - Chronic obstructive pulmonary disease or other chronic respiratory disease
  - Age 12-17 years of age with at least ONE of the following:
    - BMI  $\geq 85$ th percentile for age and gender based on CDC [growth charts](#)
    - Sickle cell disease; congenital or acquired heart disease; neurodevelopmental disorders (e.g. cerebral palsy); medically-related technological dependence (e.g. tracheostomy, gastrostomy, or positive pressure ventilation unrelated to COVID-19); asthma, reactive airway or other chronic respiratory disease that requires daily medication for control.

*Monoclonal antibodies are NOT authorized for use in patients who are hospitalized due to COVID-19 or who require supplemental  $O_2$  therapy or an increase flow rate from baseline home  $O_2$  therapy. Monoclonal antibodies may be associated with worse clinical outcomes when administered to hospitalized patients with COVID-19 requiring high flow oxygen or mechanical ventilation.*

## Resources

### [ACEP Monoclonal Antibody Tool Kit](#)

For questions regarding the distribution of monoclonal antibody supplies within AC, please contact Cynthia Frankel, RN, Alameda County Monoclonal Antibody Distribution Lead at [cynthia.frankel@acgov.org](mailto:cynthia.frankel@acgov.org)

For general questions about treatment with monoclonal antibodies, please contact Arnie Spanjers MD, Alameda County Public Health Department at [arnie.spanjers@acgov.org](mailto:arnie.spanjers@acgov.org)